J. Lipid Res. 1981, 22, 339-358
52 ROUFFY J., CHANU B., BAKIR R., GOY-LOEPER J., MIRO
I.
Lipides, lipoprotéines, apoprotéines et
manifestations cliniques artériopathiques. Path. Biol. 1983, 31,
261-270
53 ALAUPOVIC P.
Conceptual development of the classification system of
plasma lipoproteins. Protides Biol. Fluids Proc. Colloq. 1972, 19,
9-19
54 BARBARAS R., PUCHOIS P., FRUCHART J-C., AILHAUD
G.
Cholesterol efflux from cultured adipose cells is
mediated by LpAI particules but not by LpAI:All particules.
Biochem. Biophys. Res. Comm. 1987, 142, 63-69
55 KROON P., POWELL E.
Liver, lipoproteins and diseases: I. Biochemistry of
lipoprotein metabolism. J. Gastroenterol. Hepatol. 1992, 7, 214-224
5s SHEPERD J.
Lipoprotein metabolism
Drugs 1994, 47, (Suppl 2), 1-10
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 245/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
57 ISO P., BALINT J.
Formation and transport of chylomicrons by enterocytes to
the lymphatics. Am. J. Physiol. 1986, 250, G715-G726
58 CHEN S., HABIB G., YANG C., GU Z., LEE B.,
et al
Apolipoprotein B-48 is the product of a messenger RNA
with an organ-specific in-frame stop codon. Science 1987, 238,
363-366
59 ILLINGWORTH R.
Lipoprotein metabolism.
Am. J. Kid. Dis. 1993, 22, 90-97
60 GREGG R., BREWER H.
The role of apolipoprotein E and lipoprotein receptors in
modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins
in human.
Clin. Chem. 1988, 34, B28-B32
61 CHEN I., REAVEN G.
Intestinally-derived lipoproteins: metabolism and
clinical significance. Diabetes / Metabolism Reviews 1991, 7,
191-208
62 BROWN M., KOVANEN P., GOLDSTEIN J.
Regulation of plasma cholestérol by lipoprotein
receptors. Science 1981, 212, 628-635
63 GOLDSTEIN J., BROWN M., ANDERSON R., RUSSEL D.,
SCHNEIDER W. Receptor-mediated endocytosis: concepts emerging from the LDL
receptor system. Ann. Rev. Cell Biol. 1985, 1, 1-39
64 BENLIAN P., LOUX N.
Hétérogénéité des
mutations du récepteur LDL dans l'hypercholestérolémie
familiale. Médecin / Science 1991, 7, 1052-1060
65 NESTEL P.
High-density lipoprotein turnover. Am. Heart J. 1987,
113, 518-521
ss FRUCHART J-C., AILHAUD G., BARD J-M
Heterogeneity of high-density lipoprotein particules.
Circulation 1993, 87, (Suppl Ill), III-22-III-27
67 BROUTIN H., PUCHOIS P., AILHAUD G., BARBARAS R.,
TORPIER G., FRUCHART J-C. Récepteurs et
hétérogénéité moléculaire des
particules lipoprotéiques contenant l'apolipoprotéine A-I. Ann.
Biol. Clin. 1988, 46, 16-23
ss STAMPFER M., SACKS F., SALVINI S., WILLETT W.,
HENNEKENS C.
A prospective study of cholesterol, apolipoproteins, and
the risk of myocardial infarction. N. Engl. J. Med. 1991, 325,
373-381
69 GORDON D.J., PROBSTFIELD J.L., GARRISON
R.J., NEATON J.D., CASTELLI W.P. et al. High-density lipoprotein cholesterol
and cardiovascular disease. Four prospective American studies. Circulation
1989, 79, 8-15
70 MEZDOUR H., MONTE G., FRUCHART
J-C
Transfert du cholestérol plasmatique et
athérosclérose Ann. Biol. Clin. 1994, 52, 95-102
71 LUC G., LECERF J-M., BARD J-M., HACHULLA
E., FRUCHART J-C., DEVULDER B.
Cholestérol et athérosclérose. Paris
MASSON Editeur, 1991.
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 246/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
72 TURPIN G.
Pourquoi, Quand, Comment traiter les
dyslipoprotéinémies ? Dijon, Editions laboratoires FOURNIER -
THYLMER, 1991.
73 DEMUTH K., MYARA I. MOATTI N.
Biologie de la cellule endothéliale et
athérogenèse. Ann. Biol. Clin. 1995, 53, 171-189
74 CAMPBELL J., CAMPBELL G.
The role of smooth muscle cells in atherosclerosis. Curr.
Opin. Lipidol. 1994, 5, 323-330
75 STRONG J.P.
The natural history of atherosclerosis in childhood. Ann.
N Y Acad. Sci. 1991, 623, 9-15
76 STRONG J.P.
Coronary atherosclerosis in soldiers.
A clue to the natural history of atherosclerosis in the
young. JAMA 1986, 256, 2863-2866
77 PDAY Research Group
Natural history of aortic and coronary atherosclerotic
lesions in youth. Findings from the PDAY Study.
Arterioscler. Throm. 1993, 13, 1291-1298.
78 Mc GILL H.
The pathogenesis of atherosclerosis. Clin. Chem.1988, 34,
B33-B39
79 SOLBERG L., STRONG J.P.
Risk factors and atherosclerosis. A review of autopsiy
studies. Arteriosclerosis 1983, 3, 187-198
80 STRONG J.P.
Natural history and risk factors for early human
atherogenesis. Clin. Chem. 1995, 41, 134-138
81 ROSS R., GLOMSET J.A.
The pathogenesis of atherosclerosis. New Engl. J. Med.
1976, 295, 369-377.
82 O'BRIEN K., CHAIT A.
The biology of the arterial wall in atherogenesis. Med.
Clin. North Amer. 1994, 78, 41-67.
83 BROWN M.S., GOLDSTEIN J.L.
Lipoprotein metabolism in the macropage: Implication for
cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 1983, 52,
223-261
84 GOLDSTEIN J.L., HO Y.K., BASU S.K., BROWN
M.S.
Binding site on macrophages that mediates uptake and
degradation of acetylated low density lipoprotein, producing massive
cholesterol deposition.
Proc. Natl. Acad. Sci. USA 1980, 76, 333-337
85 FOGELMAN A.M., SHESCHTER I., SEAGER J., HOKOM M.,CHILD
J.S., EDWARDS P.A. Malondialdahyde alteration of low density lipoproteins leads
to cholesteryl ester accumulation in human monocyte-macrophages.
Proc. Natl. Acad. Sci. USA 1980, 77,
2214-2218
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 247/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
86 FARUQUI R.M., DI CORLETO P.E.
Mechanisms of monocyte recruitment and accumulation. Br.
Heart J. 1993, 69 (Suppl), S 19-S 29
87 WITZUM J.L.
Role of oxidized low density lipoprotein in
atherogenesis. Br. Heart J. 1993, 69 (Suppl), S 12-S 18
88 STOCKER R.
Lipoprotein oxidation: mechanistic aspects,
methodological approaches and clinical relevance. Curr. Opin. Lipidol. 1994, 5,
102-109
89 ZILVERSMIT D.
Atherogenesis: a postprandial phenomenon. Circulation
1979, 60, 473-485
9° ZILVERSMIT D.
Atherogenic nature of triglycerides, postprandial
lipidemia, and triglyceride-rich remnant lipoproteins. Clin. Chem. 1995, 41,
153-158
91 BERSOT
Fat feeding in humans induced lipoproteins of density
< 1.006 that are enriched in apo(a) and that cause lipid accumulation in
macrophages.
| 
